Adimab, LLC, a Lebanon, NH-based company that discovers fully human antibodies, has closed an over-subscribed Series F financing of undisclosed amount.
The additional funds were raised entirely from existing investors.
The company intends to use the capital to pursue complementary opportunities. As stated by CEO Tillman Gerngross, Adimab is accelerating the expansion of its platform to include additional applications such as the development of bi-specific antibodies, antibody-drug conjugates, targeting cell based antigens including GPCRs and ion channels, as well as preclinical manufacturing and mammalian cell line development.
Errik Anderson is Chief Operating Officer of the company.